Safety of Combined Targeted and Helixor(®) Viscum album L. Therapy in Breast and Gynecological Cancer Patients, a Real-World Data Study

Background: Newer personalized medicines including targeted therapies such as PARP inhibitors and CDK 4/6 inhibitors have been shown to improve the survival of breast and gynaecological cancer patients. However, efficacy outcomes may be ham5pered by treatment discontinuation due to targeted therapy-...

Descripción completa

Detalles Bibliográficos
Autores principales: Schad, Friedemann, Thronicke, Anja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916034/
https://www.ncbi.nlm.nih.gov/pubmed/36767928
http://dx.doi.org/10.3390/ijerph20032565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916034/
https://www.ncbi.nlm.nih.gov/pubmed/36767928
http://dx.doi.org/10.3390/ijerph20032565

Ejemplares similares